Bridget works as a Senior Research Officer in the Disease Elimination program, with a specific focus on viral hepatitis projects in low- and middle-income countries. She currently works on the TREAT-HEP Myanmar project and the HepC CUTTS project.
Bridget completed a Bachelor of Arts (International Studies) at RMIT and her honours in Health Sciences through Monash University at the Burnet Institute. Her honours project focussed on acceptability of HIV pre-exposure prophylaxis among men who have sex with men in Myanmar. In 2022, Bridget completed her PhD exploring how to provide hepatitis C testing and treatment in resource-constrained settings using implementation science and health service delivery research methods.
Her work involved evaluating hepatitis C treatment programs in specialist and primary care settings in Myanmar, including the CT2 Study and evaluation of the National Hepatitis Control Program.
BMC Health Services Research
Bridget Draper, Anna L. Bowring, Jessica Howell
Drug and Alcohol Review
Paul Dietze, Ashleigh C. Stewart, Penny Hill, Bridget Draper, M. David Curtis, Amy Kirwan
JGH Open
Bridget Draper, Anna Palmer, Margaret Hellard, Nick Scott
This project delivers hepatitis C prevention, testing and treatment services and hepatitis B testing and vaccination services.
This project will generate evidence on how to improve hepatitis C prevention and care for people who inject drugs in low-and middle-income countries.
This project addresses critical knowledge gaps in Australian and global efforts to eliminate hepatitis C as a public health threat by 2030.
A partnership aimed at increasing hepatitis C treatment uptake among people who inject drugs (PWID) using nurse-led models of care in community and prison settings.
This study examined the feasibility of a community-based testing and treatment program for hepatitis C.
Newly published Burnet study demonstrates the feasibility and effectiveness of simplified treatment of hepatitis C in Myanmar.
Burnet Institute is a key partner in a new global harm reduction program aiming to reduce the impact of hepatitis C among at-risk groups thanks to funding from global health agency Unitaid.